Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-lable, Multi Center Study of Sintilimab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Curative Hepatic Resection

NCT04682210 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04682210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04682210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-lable, Multi Center Study of Sintilimab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Curative Hepatic Resection
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2020
Completion date
December 31, 2024
Enrollment
246 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, hcc, immunotherapy